tiprankstipranks
Cocrystal Pharma Inc (COCP)
NASDAQ:COCP

Cocrystal Pharma (COCP) Income Statement

984 Followers

Cocrystal Pharma Income Statement

Last quarter (Q4 2023), Cocrystal Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Cocrystal Pharma's net income was $-4.46M. See Cocrystal Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 2.01M$ 6.56M
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 8.34M$ 18.56M$ -18.14M$ 14.22M$ 11.60M$ 8.87M
Operating Income
$ -8.34M$ -18.56M$ -18.14M$ -14.22M$ -9.59M$ -2.30M
Net Non Operating Interest Income Expense
$ 640.00K$ 640.00K$ -2.00K$ -4.00K$ -8.00K$ -19.00K
Other Income Expense
--$ 20.70M$ -49.00K$ -54.00K$ -45.85M
Pretax Income
$ -10.96M$ -17.98M$ -38.84M$ -14.19M$ -9.65M$ -48.17M
Tax Provision
----$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -7.76M$ -17.98M$ -38.84M$ -14.19M$ -9.65M$ -48.17M
Basic EPS
$ -1.90$ -1.87$ -4.77-$ -0.17$ -1.51
Diluted EPS
$ -1.90$ -1.87$ -4.77$ -1.92$ -0.17$ -1.51
Basic Average Shares
$ 38.60M$ 9.65M$ 8.14M$ 7.36M$ 55.22M$ 31.86M
Diluted Average Shares
$ 38.60M$ 9.65M$ 8.14M$ 7.36M$ 55.22M$ 31.86M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 8.34M$ 18.56M$ 38.83M$ 14.22M$ 11.60M$ 8.87M
Net Income From Continuing And Discontinued Operation
$ -17.98M$ -17.98M$ -38.84M$ -14.19M$ -9.65M$ -48.17M
Normalized Income
$ -7.51M-$ -9.06M-$ -9.59M$ -2.32M
Interest Expense
----$ 8.00K$ 19.00K
EBIT
$ -10.98M$ -21.16M$ -35.63M$ -14.18M$ -9.64M$ -48.15M
EBITDA
$ -10.67M$ -21.16M$ -35.45M$ -13.99M$ -9.48M$ -47.90M
Currency in USD

Cocrystal Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis